Cargando…
Advancing Academic Cancer Clinical Trials Recruitment in Canada
The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address the decline in academic cancer clinical trials (ACCT) activity. Funding was provided to cancer centres to conduct a Portfolio of ACCTs. Larger centres received core funding and were paired with smaller centres to e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395528/ https://www.ncbi.nlm.nih.gov/pubmed/34436014 http://dx.doi.org/10.3390/curroncol28040248 |
_version_ | 1783744195204218880 |
---|---|
author | Xu, Rebecca Y. Kato, Diana Pond, Gregory R. Sundquist, Stephen Schoales, James Lalani, Saher Dancey, Janet E. |
author_facet | Xu, Rebecca Y. Kato, Diana Pond, Gregory R. Sundquist, Stephen Schoales, James Lalani, Saher Dancey, Janet E. |
author_sort | Xu, Rebecca Y. |
collection | PubMed |
description | The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address the decline in academic cancer clinical trials (ACCT) activity. Funding was provided to cancer centres to conduct a Portfolio of ACCTs. Larger centres received core funding and were paired with smaller centres to enable support and sharing of resources. All centres were eligible for incentive-based funding for recruitment above pre-3CTN baseline. Established performance measures were collected and tracked. The overall recruitment target was 50% above pre-3CTN baseline by Year 4. An analysis was completed to identify predictive success factors and descriptive statistics were used to summarize site characteristics and outcomes. From 2014–2018, a total of 11,275 patients were recruited to 559 Portfolio trials, an overall increase of 59.6% above pre-3CTN baseline was observed in Year 4. Twenty-five (51%) adult centres met the Year 4 recruitment target and the overall recruitment target was met within three years. Three factors that correlated with sites’ achieving recruitment targets were: time period, region and number of baseline trials. 3CTN was successful in meeting its objectives and will continue to support ACCTs and member cancer centres, monitor performance over time and seek continued funding to ensure success, better trial access and outcomes for patients. |
format | Online Article Text |
id | pubmed-8395528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83955282021-08-28 Advancing Academic Cancer Clinical Trials Recruitment in Canada Xu, Rebecca Y. Kato, Diana Pond, Gregory R. Sundquist, Stephen Schoales, James Lalani, Saher Dancey, Janet E. Curr Oncol Review The Canadian Cancer Clinical Trials Network (3CTN) was established in 2014 to address the decline in academic cancer clinical trials (ACCT) activity. Funding was provided to cancer centres to conduct a Portfolio of ACCTs. Larger centres received core funding and were paired with smaller centres to enable support and sharing of resources. All centres were eligible for incentive-based funding for recruitment above pre-3CTN baseline. Established performance measures were collected and tracked. The overall recruitment target was 50% above pre-3CTN baseline by Year 4. An analysis was completed to identify predictive success factors and descriptive statistics were used to summarize site characteristics and outcomes. From 2014–2018, a total of 11,275 patients were recruited to 559 Portfolio trials, an overall increase of 59.6% above pre-3CTN baseline was observed in Year 4. Twenty-five (51%) adult centres met the Year 4 recruitment target and the overall recruitment target was met within three years. Three factors that correlated with sites’ achieving recruitment targets were: time period, region and number of baseline trials. 3CTN was successful in meeting its objectives and will continue to support ACCTs and member cancer centres, monitor performance over time and seek continued funding to ensure success, better trial access and outcomes for patients. MDPI 2021-07-28 /pmc/articles/PMC8395528/ /pubmed/34436014 http://dx.doi.org/10.3390/curroncol28040248 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Xu, Rebecca Y. Kato, Diana Pond, Gregory R. Sundquist, Stephen Schoales, James Lalani, Saher Dancey, Janet E. Advancing Academic Cancer Clinical Trials Recruitment in Canada |
title | Advancing Academic Cancer Clinical Trials Recruitment in Canada |
title_full | Advancing Academic Cancer Clinical Trials Recruitment in Canada |
title_fullStr | Advancing Academic Cancer Clinical Trials Recruitment in Canada |
title_full_unstemmed | Advancing Academic Cancer Clinical Trials Recruitment in Canada |
title_short | Advancing Academic Cancer Clinical Trials Recruitment in Canada |
title_sort | advancing academic cancer clinical trials recruitment in canada |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395528/ https://www.ncbi.nlm.nih.gov/pubmed/34436014 http://dx.doi.org/10.3390/curroncol28040248 |
work_keys_str_mv | AT xurebeccay advancingacademiccancerclinicaltrialsrecruitmentincanada AT katodiana advancingacademiccancerclinicaltrialsrecruitmentincanada AT pondgregoryr advancingacademiccancerclinicaltrialsrecruitmentincanada AT sundquiststephen advancingacademiccancerclinicaltrialsrecruitmentincanada AT schoalesjames advancingacademiccancerclinicaltrialsrecruitmentincanada AT lalanisaher advancingacademiccancerclinicaltrialsrecruitmentincanada AT danceyjanete advancingacademiccancerclinicaltrialsrecruitmentincanada |